• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Trevena Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/18/24 4:43:33 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVN alert in real time by email
    false 0001429560 0001429560 2024-06-13 2024-06-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 13, 2024

     

    TREVENA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-36193   26-1469215
    (State or other jurisdiction of
    incorporation)
      (Commission File No.)     (IRS Employer
    Identification No.)

     

    955 Chesterbrook Boulevard, Suite 110

    Chesterbrook, PA 19087

    (Address of principal executive offices and zip code)

     

    (610) 354-8840

    (Registrant’s telephone number, including area code) 

     

    n/a

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  Trading Symbol(s)  Name of each exchange on which registered
    Common Stock, $0.001 par value  TRVN  The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

    Item 5.07Submission of Matters to a Vote of Security Holders.

     

    In connection with the Annual Meeting of Trevena, Inc. held on June 13, 2024 (the “Annual Meeting”), there were 18,321,010 shares outstanding as of the April 19, 2024 record date, of which 10,379,137 shares, or approximately 56.65%, were present or represented by proxy at the Annual Meeting. With respect to the matters submitted for a vote of stockholders at the Annual Meeting:

     

    (i)Proposal 1 — each of the Class II directors nominated were elected to serve until the expiration of their term as provided in the proxy statement.

     

    (ii)Proposal 2 — the election of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified.

     

    (iii)Proposal 3 – the compensation of the Company’s named executive officers as disclosed in the proxy statement was approved on a non-binding advisory basis.

     

    (iv)Proposal 4 – the amendment to the Trevena, Inc. 2023 Equity Incentive Plan (the “2023 Plan”), to increase the number of shares of common stock available for issuance under the 2023 Plan as disclosed in the proxy statement was approved.

     

    (v)Proposal 5 – the amendment to the Company’s Amended and Restated Certificate of Incorporation (as amended, the “Restated Certificate”) to effect a reverse stock split of the outstanding shares of common stock by a ratio of any whole number between 1-for-2 and 1-for-25 (the “Reverse Stock Split”), at any time prior to August 28, 2024, with the exact ratio to be set within that range at the discretion of the Board of Directors, without further approval or authorization of our stockholders, was approved.

     

    (vi)Proposal 6 - the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve Proposal 4 or Proposal 5, was approved.

     

    Set forth below are the voting results for each such matter.

     

    Proposal 1 - Election of Directors.

     

    The following three Class II directors were elected to serve for three-year terms until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified.

     

    Name   Votes For     Votes Withheld     Broker Non-Votes  
    Jake R. Nunn   5,585,376       1,039,685       3,754,076    
    Marvin Johnson, Jr.   5,582,069       1,042,992       3,754,076    
    Mark Corrigan, M.D.   5,225,250       1,399,811       3,754,076    

     

    Proposal 2 - Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

     

    For     Against     Abstain     Broker Non-Votes  
    9,232,888     1,002,350     143,899     0  

     

     

     

     

    Proposal 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement.

     

    For     Against     Abstain     Broker Non-Votes  
    4,206,157     2,317,342     101,562     3,754,076  

     

    Proposal 4 - Approval of the amendment to the Trevena, Inc. 2023 Equity Incentive Plan to increase the number of shares of common stock available for issuance under the 2023 Plan as disclosed in the proxy statement.

     

    For     Against     Abstain     Broker Non-Votes  
    4,031,683     2,470,228     123,150     3,754,076  

     

    Proposal 5 - Approval of the amendment to the Amended and Restated Certificate of Incorporation (as amended, the “Restated Certificate”) to effect a reverse stock split of our outstanding shares of common stock by a ratio of any whole number between 1-for-2 and 1-for-25 (the “Reverse Stock Split”), at any time prior to August 28, 2024, with the exact ratio to be set within that range at the discretion of our Board of Directors, without further approval or authorization of our stockholders as disclosed in the proxy statement.

     

    For     Against     Abstain     Broker Non-Votes  
    6,922,166     3,233,085     223,886     0  

     

    Proposal 6 – Approval of the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve Proposal 4 or Proposal 5.

     

    For     Against     Abstain     Broker Non-Votes  
    7,048,020     3,232,813     98,304     0  

     

     

     

     

    SIGNATURES

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      TREVENA, INC.
       
    Date: June 18, 2024 By: /s/ Barry Shin
        Barry Shin
        Executive Vice President, Chief Operating Officer and Chief Financial Officer

     

     

     

    Get the next $TRVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRVN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRVN
    SEC Filings

    View All

    Trevena Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - TREVENA INC (0001429560) (Filer)

    5/15/25 8:09:22 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Trevena Inc.

    25-NSE - TREVENA INC (0001429560) (Subject)

    4/8/25 9:20:54 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by Trevena Inc.

    NT 10-K - TREVENA INC (0001429560) (Filer)

    3/31/25 4:01:19 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trevena Reports Third Quarter 2024 Results and Provides Business Update

    CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates $2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a non-dilutive, $2 million tranche in connection with an amendment (the "Amendment") to its existing ex-US royalty financing with R-Bridge Healthcare Fund ("R-Bridge"). The Compa

    11/7/24 7:01:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevena Announces Receipt of Nasdaq Delisting Notification

    CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Company until October 2, 2024, to regain comp

    10/4/24 4:05:00 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevena Announces Reverse Stock Split

    CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on Tuesday, August 13, 2024. Trevena's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "TRVN" and will begin trading on a split-adjusted basis when the market opens on Tu

    8/8/24 4:05:00 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Sutton Katrine claimed ownership of 942 shares (SEC Form 3)

    3 - TREVENA INC (0001429560) (Issuer)

    12/6/24 4:39:03 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acting CMO Demitrack Mark covered exercise/tax liability with 885 shares, decreasing direct ownership by 7% to 11,363 units (SEC Form 4)

    4 - TREVENA INC (0001429560) (Issuer)

    10/10/24 5:08:47 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acting COO and CFO Shin Barry covered exercise/tax liability with 806 shares, decreasing direct ownership by 7% to 11,543 units (SEC Form 4)

    4 - TREVENA INC (0001429560) (Issuer)

    10/10/24 5:07:55 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Trevena

    Oppenheimer initiated coverage of Trevena with a rating of Market Perform

    3/15/21 7:02:03 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Trevana

    Oppenheimer initiated coverage of Trevana with a rating of Perform

    3/15/21 6:50:29 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Leadership Updates

    Live Leadership Updates

    View All

    Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

    CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company's Board of Directors, effective July 18 2023. "We are pleased to welcome Mark to Trevena's Board of Directors," said Carrie Bourdow, Trevena's President and CEO. "Mark has over 30 years of experience in the life sciences industry and broad neuroscience expertise. He will be an invaluable member of the Board and guide to the management team as we continue to execute on our corporate

    7/20/23 7:00:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Imvax Appoints John M. Limongelli as Chief Legal Officer

    Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021. "John's breadth of experience in the biopharma industry, his deep technical acumen, and his expertise at helping build strong corporate practices will be of invaluable benefit to our leadership team," said John Furey, Chief Executive Officer. "As we work to expand our platform to address a variety of solid tumors, John's expertise will be an essential part of the development of these assets." Mr. Limongelli is an accomplished executive officer and lawyer with near

    9/16/21 8:00:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trevena Inc.

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    11/14/24 4:43:11 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Trevena Inc.

    SC 13G - TREVENA INC (0001429560) (Subject)

    9/19/24 4:09:55 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Trevena Inc. (Amendment)

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    2/14/24 2:34:30 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Financials

    Live finance-specific insights

    View All

    Trevena Reports Third Quarter 2023 Results and Provides Business Update

    Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK presented at American Society of Anesthesiologists (ASA) Conference $15 million tranche from ex-US royalty-based financing agreement received in September Company to host conference call today, November 14, 2023 at 8:00 a.m. ET CHESTERBROOK, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for pat

    11/14/23 7:00:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

    CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023. The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Office

    11/9/23 7:00:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

    $15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Three OLINVYK abstracts accepted for presentation at upcoming American Society of Anesthesiologists Meeting in 4Q 2023 Company to participate in upcoming HC Wainwright conference (September 11-13) Company to Hold Conference Call on Wednesday, September 6 at 8 a.m. Eastern Time to discuss TRV045 Proof-of-Concept Data CHESTERBROOK, Pa., Sept. 06, 2023 (GLOBE NEWSWI

    9/6/23 7:01:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care